Abstract
(BJOG 2017;124:1567–1574) Antenatal corticosteroid (ACS) treatment is recommended for all women who are at risk of preterm birth before 34 weeks’ gestation and reduces neonatal death, respiratory distress syndrome, intraventricular hemorrhage, and other adverse events in preterm infants. Data regarding the effects of ACS on extremely preterm infants is limited. This study aimed to investigate the impact of the administration-to-birth time interval on survival in extremely preterm infants.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
